| Quarter | Score |
|---|---|
| 2022-Q1 | 49.5 |
| 2022-Q3 | 70.1 |
| 2022-Q4 | 49.3 |
| 2023-Q2 | 63.5 |
| 2023-Q3 | 48.4 |
| 2023-Q4 | 76.0 |
| 2024-Q1 | 74.2 |
| 2024-Q2 | 80.9 |
| 2024-Q3 | 58.8 |
| 2024-Q4 | 59.3 |
| 2025-Q1 | 74.7 |
| 2025-Q2 | 63.4 |
| 2025-Q3 | 63.8 |
| 2025-Q4 | 65.0 |
| 2026-Q1 | 76.2 |
| 2026-Q2 | 76.7 |
Funds reducing exposure or consensus momentum fading
Trading +28.9% above funds' purchase price — elevated pullback risk
2 of 18 tracked funds hold AVGO. Avg conviction: 0.4%. Net trimming. First tracked at $275.13 (current +28.9% vs tracked).
Appaloosa Management has 0.7% in this stock
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| Appaloosa Management | 0.7% | New Buy |
| Citadel Advisors | 0.1% | Reduce |